Structural Heart
Our work with the structure of the heart dates back to 1977, when we introduced a revolutionary mechanical heart valve that had no welds, joints, or bends that could eventually weaken the valve's structure. Since then, we've expanded our expertise into heart valve repair and tissue valves, including the world's first transcatheter valve in 2006.
Key Product Categories
Heart Valve Repair
We develop repair products to help address heart valve disease and function. These rings and bands are sewn around the base of a damaged heart valve to provide shape and stability so the valve can open and close properly.
Conditions
Mechanical Valves (Surgical Replacement)
These replacement mechanical valves – to help address heart valve disease and function – are made of a strong material, such as titanium or carbon. A surgeon first removes the damaged heart valve and then sews the artificial valve in place.
Conditions
Tissue Valves (Surgical Replacement)
These replacement tissue valves – to help address heart valve disease and function – are built from animal tissue. A surgeon first removes the damaged heart valve and then sews the artificial valve in place.
Conditions
Tissue Valves (Transcatheter Replacement)
Medtronic has led the development of transcatheter valves worldwide, including the first transcatheter valve approved in the world, which was approved in the United States in 2010 to treat patients with congenital heart defects.
Conditions
Tissue Stabilization Systems for Beating Heart Bypass Surgery
A tissue stabilization system immobilizes the area of the heart where the surgeon needs to graft a healthy vein or artery to replace a blocked artery. The system consists of a heart positioner and a tissue stabilizer. The heart positioner guides and holds the heart in a position that provides the best access to the blocked artery. The tissue stabilizer holds a small area of the heart still while a surgeon works on it.
Conditions
* The Medtronic Therapy for this disorder is available through a Humanitarian Device Exemption in the United States. The effectiveness of the therapy for this disorder has not been demonstrated.
For Physicians
For heart valve repair and replacement products, see our Cardiac and Vascular Products.
- Print Page
- E-mail Page
- A
- A
- A Text Size
Additional information
At a Glance
FY2012 Revenue
Structural Heart accounted for $1 billion, or 6%, of our total $16 billion FY2012 revenue.
President
John Liddicoat, M.D.
Headquarters
Mounds View, Minnesota